Skip to main content

Table 2 Estimated discounted lifetime societal, fiscal and medical cost burden for immunized and non-immunized cohorts of males and females

From: Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework

Outcome

Immunized

Non-immunized

Incremental

BOD-fiscal in terms of discounted lifetime gross tax loss due to premature mortality

€ 117,502,550

€ 130,864,666

-€ 13,362,116

BOD-societal in terms of discounted lifetime productivity loss due to premature mortality

€ 209,825,982

€ 233,686,903

-€ 23,860,921

Discounted lifetime HPV– related medical costs

€ 692,164,462

€ 863,973,983

-€ 171,809,521

Vaccination investment cost

€107,525,880

€ -

€ 107,525,880